Literature DB >> 6310833

A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months.

P J Morris, M E French, M S Dunnill, A G Hunnisett, A Ting, J F Thompson, R F Wood.   

Abstract

Thirty-five patients given an HLA-DR-incompatible cadaver kidney that was diuresing immediately after transplantation were randomly allocated to treatment with cyclosporine alone for 3 months followed by conversion to azathioprine and prednisolone (AP), or to conventional treatment with AP. Although many patients had to be converted to AP before 90 days because of rejection requiring more than two treatment courses of high-dose i.v. methylprednisolone, 16 of 21 grafts were functioning at 3 months, and 12 of 14 grafts in the control group were functioning. However 3 further grafts were lost from chronic rejection in the control group, and none were lost from chronic rejection in the cyclosporine group. All but one patient on cyclosporine had depressed renal function, and in all these patients function improved on conversion to AP. This depression of renal function is attributed both to cyclosporine nephrotoxicity and to a low-grade rejection reaction, the latter suggesting that the addition of steroids to cyclosporine might be beneficial in some patients. The strategy of a three-month course of cyclosporine followed by conversion to AP provides satisfactory immunosuppression, and it may be of value if long-term side effects of cyclosporine emerge with further experience.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310833     DOI: 10.1097/00007890-198309000-00009

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts.

Authors:  N L Tilney; A Chang; E L Milford; W D Whitley; J M Lazarus; E L Ramos; T B Strom; C B Carpenter; R L Kirkman
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

2.  The selective use of antilymphocyte serum for cyclosporine treated patients with renal allograft dysfunction.

Authors:  F L Delmonico; H Auchincloss; R H Rubin; P S Russell; N Tolkoff-Rubin; L T Fang; A B Cosimi
Journal:  Ann Surg       Date:  1987-11       Impact factor: 12.969

3.  Cytomegalovirus as a risk factor in living-related renal transplantation. A prospective study.

Authors:  R Pollak; P L Barber; B F Prusak; M F Mozes
Journal:  Ann Surg       Date:  1987-03       Impact factor: 12.969

Review 4.  The utility of cyclosporine weaning in renal transplantation.

Authors:  R Loertscher; L Blier; O Steinmetz; C Nohr
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

5.  Experience with cyclosporine and steroids in clinical renal transplantation.

Authors:  N L Tilney; E L Milford; J L Araujo; T B Strom; C B Carpenter; R L Kirkman
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

6.  Improved outcome of renal transplantation with cyclosporine compared with azathioprine--experience in 33 recipients followed for over one year.

Authors:  T Yasumura; Y Ohmori; I Aikawa; M Fukuda; S Suzuki; I Nakai; S Matsui; T Oka
Journal:  Jpn J Surg       Date:  1986-05

7.  Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis.

Authors:  B A Dijkmans; A W van Rijthoven; H S Goei The; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS): a study protocol for a double-blind, randomised, placebo-controlled, proof-of-concept study.

Authors:  Per Ederoth; Edgars Grins; Alain Dardashti; Björn Brondén; Carsten Metzsch; André Erdling; Shahab Nozohoor; Arash Mokhtari; Magnus J Hansson; Eskil Elmér; Lars Algotsson; Stefan Jovinge; Henrik Bjursten
Journal:  BMJ Open       Date:  2016-12-15       Impact factor: 2.692

9.  Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model.

Authors:  Shinya Morita; Kazunobu Shinoda; Tadashi Yoshida; Masayuki Shimoda; Yoshihiko Kanno; Ryuichi Mizuno; Hidaka Kono; Hiroshi Asanuma; Ken Nakagawa; Kazuo Umezawa; Mototsugu Oya
Journal:  BMC Pharmacol Toxicol       Date:  2020-08-12       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.